Business
Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease
Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n Issued claims include therapeutic protein, gene therapy and cell therapy applicationsPatent extends MANF Therapeutics' exclusivity for MANF treatment of Parkinson's disease in Japan into 2029 SAN FRANCISCO, Dec. 20, 2017 (GLOBE NEWSWIRE) -- via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned subsidiary MANF Therapeutics, Inc. was issued a patent by the Japan Patent Office entitled \"Neurodegenerative Disorders\" covering the use of MANF as a treatment for Parkinson's disease. The issued patent extends coverage for MANF Therapeutics' use of MANF in the treatment of Parkinson's in Japan into 2031.\n The key claim issued in this patent is \"Use of MANF for the manufacture of a medicament for administration to the substantia nigra region of the brain for treating Parkinson's disease.\" The substantia nigra is a key area of the brain where dopamine producing neurons degenerate in Parkinson's disease. Additional claims covering combinations with MANF and other therapeutic moieties were also granted, as well as gene therapy and cell therapy claims. This patent adds to Amarantus' extensive international intellectual property portfolio covering compositions of matter, methods of use and formulations for MANF in numerous disease indications. Significant pre-clinical efficacy and delivery data supporting the use of MANF in the treatment of Parkinson's disease is available in peer-reviewed scientific journals, as well as summary results that Amarantus previously made publicly available. Certain data is available at the links below: Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's DiseaseConvection-enhanced delivery of MANF Volume of distribution analysis in porcine putamen and substantia nigraComparison and Actions of MANF and GDNF in Rodent Models of Parkinson's Disease A Whitepaper on MANF commissioned by Amarantus in Q2/2013 is available here: http://content.stockpr.com/amarantus/files/pdf/MANF+WhitePaper+2013-04-30+FINAL.pdf About Amarantus Bioscience Holdings, Inc. Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagno...